NO20050205L - Veksthormon frigjorende peptider - Google Patents

Veksthormon frigjorende peptider

Info

Publication number
NO20050205L
NO20050205L NO20050205A NO20050205A NO20050205L NO 20050205 L NO20050205 L NO 20050205L NO 20050205 A NO20050205 A NO 20050205A NO 20050205 A NO20050205 A NO 20050205A NO 20050205 L NO20050205 L NO 20050205L
Authority
NO
Norway
Prior art keywords
bzl
growth hormone
2nal
bip
bpa
Prior art date
Application number
NO20050205A
Other languages
English (en)
Inventor
Zheng Xin Dong
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of NO20050205L publication Critical patent/NO20050205L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40Transferrins, e.g. lactoferrins, ovotransferrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/60Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1016Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1024Tetrapeptides with the first amino acid being heterocyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

Det er beskrevet peptider og peptidomimetiske forbindelser generelt med formel (I) og farmasøytisk akseptable salter derav, som er anvendelige som GHRP-analoger: 51-A1- A2- A3- A4- A5- R2 (I) eller et farmasøytisk akseptabelt salt derav, hvor: A1 er Aib, Apc eller lnp; A2 er D-Bal, D-Bip, D-Bpa, D-Dip, D-1 Nal, D-2Nal, D-Ser(Bzl) eller D-Trp; A3 er D-Bal, D-Bip, D-Bpa, D-Dip, D-1 Nal, D-2Nal, D-Ser(Bzl) eller D-Trp; A4 er 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl); A5 er Apc, Dab, Dap, Lys, Orn eller er deletert; R1 er hydrogen, (C1-6)alkyl, (C5-14)aryl, (C1-6 )alkyl(C5-14)aryl, (C3-8)cykloakyl eller (C2-10) acyl; og R2 er OH eller NH2; og farmasøytiske pr eparater og metoder for anvendelse derav.
NO20050205A 2002-08-09 2005-01-13 Veksthormon frigjorende peptider NO20050205L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40226302P 2002-08-09 2002-08-09
PCT/US2003/024834 WO2004014415A1 (en) 2002-08-09 2003-08-08 Growth hormone releasing peptides

Publications (1)

Publication Number Publication Date
NO20050205L true NO20050205L (no) 2005-03-04

Family

ID=31715820

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050205A NO20050205L (no) 2002-08-09 2005-01-13 Veksthormon frigjorende peptider

Country Status (23)

Country Link
US (7) US7456253B2 (no)
EP (2) EP1542716B1 (no)
JP (2) JP4365319B2 (no)
KR (1) KR100967572B1 (no)
CN (3) CN1674927A (no)
AR (2) AR040965A1 (no)
AT (1) ATE447411T1 (no)
AU (1) AU2003259062B2 (no)
BR (2) BR122016015852B8 (no)
CA (1) CA2494300C (no)
CZ (1) CZ20041254A3 (no)
DE (1) DE60329923D1 (no)
DK (1) DK1542716T3 (no)
ES (1) ES2334223T3 (no)
HK (1) HK1072908A1 (no)
IL (1) IL165998A (no)
MX (1) MXPA05000974A (no)
NO (1) NO20050205L (no)
PL (1) PL212138B1 (no)
RU (2) RU2323941C2 (no)
SG (1) SG177006A1 (no)
TW (1) TWI331922B (no)
WO (1) WO2004014415A1 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331922B (en) * 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
CN1688696A (zh) * 2002-09-18 2005-10-26 蒙特利尔大学医疗中心 Ghrh类似物
WO2004071448A2 (en) * 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
WO2006045314A2 (en) * 2004-10-27 2006-05-04 Gastrotech Pharma A/S Use of a growth hormone secretatogue for increasing or maintaining lean body mass and/or for treatment of chronic obstructive pulmonary disease
WO2006058539A2 (en) * 2004-11-30 2006-06-08 Gastrotech Pharma A/S Growth hormone secretagogue receptor 1a ligands
WO2007014258A2 (en) * 2005-07-22 2007-02-01 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Growth hormone secretagogues
ES2740108T3 (es) * 2005-09-29 2020-02-05 Ipsen Pharma Composición para uso en el tratamiento de dismotilidad gastrointestinal
EP1818061A1 (en) * 2005-12-02 2007-08-15 Charite-Universitätsmedizin Berlin Use of ghrelin for stimulating hair growth
CU23592A1 (es) * 2006-02-28 2010-11-11 Ct Ingenieria Genetica Biotech Método para prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos aplicando el péptido secretagogo ghrp-6
US20100227806A1 (en) 2006-03-10 2010-09-09 Tulipano Giovanni Use Of A Ghrelin Agonist To Improve Catabolic Effects Of Glucocorticoid Treatment
US8536120B2 (en) * 2006-04-28 2013-09-17 The Administrators Of The Tulane Educational Fund Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof
CA2664558C (en) * 2006-09-27 2016-11-01 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogs of ghrelin substituted at the n-terminal
CN101646448B (zh) 2007-03-12 2017-02-08 雪印惠乳业株式会社 生长激素分泌促进剂
TW200916113A (en) * 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
WO2009108364A2 (en) * 2008-02-27 2009-09-03 Ipsen Pharma S.A.S. Antagonistic analogues of ghrh
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
RU2523566C2 (ru) * 2010-03-15 2014-07-20 Ипсен Фарма С.А.С. Фармацевтическая композиция лигандов рецепторов секретагогов гормона роста
KR20140100937A (ko) * 2011-10-18 2014-08-18 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
KR101996700B1 (ko) 2011-12-23 2019-07-04 입센 메뉴팩츄링 아일랜드 리미티드 치료 펩티드의 합성 방법
US10039813B2 (en) 2012-02-07 2018-08-07 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
EP2705835A1 (en) * 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
WO2015134567A1 (en) * 2014-03-04 2015-09-11 Rhythm Pharmaceuticals, Inc. Process for the liquid phase synthesis of h-inp-(d)bal-(d)trp-phe-apc-nh2, and pharmaceutically acceptable salts thereof
WO2016138099A1 (en) 2015-02-24 2016-09-01 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
US20170121385A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
US10111929B1 (en) 2017-04-07 2018-10-30 Ez Ip, Llc Growth hormone releasing factor analogs and uses
CN113045625B (zh) * 2021-03-30 2023-11-07 成都诺和晟泰生物科技有限公司 作为生长激素促分泌素受体激动剂的多肽及其应用
CN113072617B (zh) * 2021-03-30 2023-08-08 成都诺和晟泰生物科技有限公司 一种多肽化合物及其应用
CN114805487B (zh) * 2022-06-07 2024-03-12 成都诺和晟泰生物科技有限公司 一种多肽化合物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264565A (en) 1991-01-22 1993-11-23 Affymax Technologies, N.V. Nucleic acid encoding the D2 /Ml chimeric receptor
HU224345B1 (hu) 1993-12-23 2005-08-29 Novo Nordisk A/S. Növekedési hormont felszabadító tulajdonságú peptidek, ezeket hatóanyagként tartalmazó gyógyszerkészítmények és alkalmazásuk
ZA95260B (en) * 1994-01-13 1995-09-28 Univ Columbia Synthetic receptors libraries and uses thereof
WO1996010040A1 (en) 1994-09-27 1996-04-04 Romano Deghenghi Polypeptide compounds containing d-2-alkyltryptophan capable of promoting the release of growth hormone
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US20020111461A1 (en) 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
US5776718A (en) * 1995-03-24 1998-07-07 Arris Pharmaceutical Corporation Reversible protease inhibitors
BR9608909A (pt) 1995-06-22 1999-03-02 Novo Nordisk As Composto composição farmacêutica processos para estimular a liberação do hormônio do crescimento da patuitária e aumentar a velocidade e extensão do crescimento dos animais para aumentar a produção de leite ou lã de animais ou para para doenças e uso do composto
DE69637587D1 (de) 1995-07-26 2008-08-21 Astrazeneca Ab Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen
US5932548A (en) 1998-06-03 1999-08-03 Deghenghi; Romano Lysine containing peptides for treatment of heart disease
US6124263A (en) * 1998-11-16 2000-09-26 Asta Medica Ag Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
US6468974B1 (en) * 1998-08-14 2002-10-22 The Administrators Of The Tulane Educational Fund Compounds having growth hormone releasing activity
EP1197496B8 (en) 1999-07-23 2007-10-03 Kenji Kangawa Novel peptides
CN1443198A (zh) 2000-07-24 2003-09-17 阿达纳生物科学有限公司 Ghrelin拮抗剂
TWI331922B (en) * 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
WO2006045314A2 (en) 2004-10-27 2006-05-04 Gastrotech Pharma A/S Use of a growth hormone secretatogue for increasing or maintaining lean body mass and/or for treatment of chronic obstructive pulmonary disease
ES2740108T3 (es) * 2005-09-29 2020-02-05 Ipsen Pharma Composición para uso en el tratamiento de dismotilidad gastrointestinal
US20100227806A1 (en) * 2006-03-10 2010-09-09 Tulipano Giovanni Use Of A Ghrelin Agonist To Improve Catabolic Effects Of Glucocorticoid Treatment
TW200916113A (en) * 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue

Also Published As

Publication number Publication date
RU2323941C2 (ru) 2008-05-10
US9409948B2 (en) 2016-08-09
JP4365319B2 (ja) 2009-11-18
CN102850436B (zh) 2017-06-16
EP2130548A2 (en) 2009-12-09
PL373605A1 (en) 2005-09-05
AR040965A1 (es) 2005-04-27
AU2003259062A1 (en) 2004-02-25
HK1072908A1 (en) 2005-09-16
CN101108875A (zh) 2008-01-23
CN1674927A (zh) 2005-09-28
BR122016015852B8 (pt) 2021-07-27
CN102850436A (zh) 2013-01-02
US20200017548A1 (en) 2020-01-16
US20130123170A1 (en) 2013-05-16
TWI331922B (en) 2010-10-21
EP1542716B1 (en) 2009-11-04
WO2004014415A1 (en) 2004-02-19
TW200408402A (en) 2004-06-01
US20150031615A1 (en) 2015-01-29
BR122016015852B1 (pt) 2018-06-19
EP1542716A4 (en) 2006-05-10
CZ20041254A3 (cs) 2005-04-13
IL165998A (en) 2015-09-24
KR100967572B1 (ko) 2010-07-05
JP5025668B2 (ja) 2012-09-12
JP2005535707A (ja) 2005-11-24
US20170362275A1 (en) 2017-12-21
BRPI0313273B8 (pt) 2021-05-25
AU2003259062B2 (en) 2007-06-21
US8377865B2 (en) 2013-02-19
ES2334223T3 (es) 2010-03-08
BR0313273A (pt) 2005-07-05
BRPI0313273A8 (pt) 2016-04-19
RU2005106236A (ru) 2006-01-20
KR20050034716A (ko) 2005-04-14
SG177006A1 (en) 2012-01-30
US20080242619A1 (en) 2008-10-02
ATE447411T1 (de) 2009-11-15
AR062801A2 (es) 2008-12-10
US8859729B2 (en) 2014-10-14
DE60329923D1 (de) 2009-12-17
MXPA05000974A (es) 2005-05-16
CA2494300A1 (en) 2004-02-19
CA2494300C (en) 2011-02-08
IL165998A0 (en) 2006-01-15
RU2007145026A (ru) 2009-06-10
EP1542716A1 (en) 2005-06-22
DK1542716T3 (da) 2010-02-01
US20050148515A1 (en) 2005-07-07
US7456253B2 (en) 2008-11-25
BRPI0313273B1 (pt) 2019-02-12
US20160311855A1 (en) 2016-10-27
EP2130548A3 (en) 2009-12-23
PL212138B1 (pl) 2012-08-31
JP2009149659A (ja) 2009-07-09

Similar Documents

Publication Publication Date Title
NO20050205L (no) Veksthormon frigjorende peptider
CA2272990C (en) Heptapeptide oxytocin analogues
RU96115195A (ru) Соединения со свойствами выделения (высвобождения) гормона роста
WO2011038066A4 (en) Novel npr-b agonists
US5698522A (en) 6-position modified decapeptide LHRH antagonists
KR970004039B1 (ko) 점막 투여시 흡수 촉진제로서의 시클릭 펩티드
US5491217A (en) LHRH antagonists having modified aminoacyl residues at positions 5 and 6
AU677324B2 (en) Motilin-like polypeptides with gastrointestinal motor stimulating activity
AU2014268524A1 (en) Angiotensin peptides in treating Marfan Syndrome and related disorders
CZ84893A3 (en) Method of projecting and synthesizing lhrh antagonists
EA200400603A1 (ru) Новые пептиды - аналоги гормона высвобождения гормона роста человека
JP2016026193A (ja) 点眼剤
US5071836A (en) Competitive gonadoliberin antagonists
BG106735A (bg) Пептиди за лечение на еректилна дисфункция
BRPI0500392A (pt) peptìdeos de liberação de hormÈnio do crescimento
WO1992000996A1 (en) Derivatives of pituitary posterior lobe hormones
TW386086B (en) Heptapeptide oxytocin analogues
JPH06509571A (ja) タキキニン拮抗薬としての環状ヘキサペプチドの製法およびその薬学的化合物
ES2309756T3 (es) Secretagogos pseudopeptidicos de la hormana del crecimiento.
RU98101096A (ru) Соединения, вызывающие выделение гормона роста

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application